SAN DIEGO, July 26, 2021-( BUSINESS WIRE)- Quidel Corporation (NASDAQ: QDEL) ("Quidel"), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, today announced its entry into agreements with Beckman Coulter resolving the ongoing litigation with Beckman Coulter and providing for the transition of the BNP Business to Beckman Coulter. Quidel to receive cash payments between $70 million to $75 million per year through 2029Īrrangement is expected to be EPS and Cash Flow neutral to the existing supply agreement through 2029įurther enables Quidel’s strategic focus on growing its core business
Settlement Agreement ends litigation that began in November 2017, following Quidel’s acquisition of the BNP Business from Alere, Inc.
0 kommentar(er)
